INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
03 · Corporate insiders

Form 4 filings

Officers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.

Form 4 transactions

Cluster activity · 60d

Most active filers

Companies with the most Form 4 filings
Data sources
SEC Form 43h ago
House PTR3h ago
SEC 13F3h ago
Robinhood Chain3h ago

Most active filers · 30d

  1. 01Kurtz George0B / 215S215 trades$52.62M
  2. 02SPSaba Capital Management, L.P.77B / 19S · 11 late96 trades$25.89M
  3. 03FWFogarty Patrick W0B / 90S90 trades$362K
  4. 04SJSheena Jonathan0B / 57S57 trades$3.61M
  5. 05ATAdair Kathleen Theresa52B / 0S · 52 late52 trades$18K
  6. 06AJAllaire Jeremy0B / 50S50 trades$4.26M
  7. 07Wilhelmsen Arne Alexander0B / 47S47 trades$241.96M
  8. 08SLSpeiser Michael L0B / 35S35 trades$14.00M
  9. 09RARothblatt Martine A0B / 33S33 trades$5.50M
  10. 10RJRubinstein Julie0B / 32S32 trades$5.48M

Cluster activity · 60d

  1. BUYTSMTAIWAN SEMICONDUCTOR MANUFACTURING CO LTDNov 5 – Nov 1732 insiders$917K
  2. SELLDRDDRDGOLD LTDOct 27 – Oct 2710 insiders$1.23M
  3. BUYMTDRMatador Resources CoNov 5 – Nov 109 insiders$765K
  4. SELLMSIMotorola Solutions, Inc.Nov 6 – Nov 108 insiders$40.91M
  5. SELLFFIVF5, INC.Nov 3 – Nov 58 insiders$8.37M
  6. SELLIBEXIBEX LtdNov 9 – Nov 167 insiders$3.36M
  7. SELLMGNIMAGNITE, INC.Nov 5 – Nov 127 insiders$2.27M
  8. SELLSYMSymbotic Inc.Oct 26 – Nov 27 insiders$1.98M

Form 4 transactions

71,797 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
Include
grants & admin
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
4
MA
Merriman Dwight ADirector
MDBMongoDB, Inc.
Open-market sale · 10b5-1 plan
SELL$139K
340 sh
Jan 14, 2026Jan 15, 2026
Page 1458 of 1795
← PrevNext →
traded Jan 14, 2026
+1d
SEC Form 4

Evidence

3
CM
Cannon-Brookes MichaelDirector, CEO, Co-Founder, 10% Owner
TEAMAtlassian Corp
Open-market sale · 10b5-1 plan
SELL$41K
300 sh
Jan 14, 2026Jan 15, 2026
traded Jan 14, 2026
+1dSEC Form 4

Evidence

3
PJ
Prober Charles J.Director
LIFLife360, Inc.
Option exercise · 10b5-1 plan
M—
7,930 sh
Jan 13, 2026Jan 15, 2026
traded Jan 13, 2026
+2dSEC Form 4

Evidence

3
Farquhar ScottDirector, 10% Owner
TEAMAtlassian Corp
Open-market sale · 10b5-1 plan
SELL$41K
300 sh
Jan 14, 2026Jan 15, 2026
traded Jan 14, 2026
+1dSEC Form 4

Evidence

2
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$59K
4,167 sh
Jan 13, 2026Jan 15, 2026
traded Jan 13, 2026
+2dSEC Form 4

Evidence

2
BR
Bentley Sheldon Richard10% Owner, Founder
CSAICLOUDASTRUCTURE, INC.
Open-market sale · 10b5-1 plan
SELL$21K
25.0K sh
Jan 14, 2026Jan 15, 2026
traded Jan 14, 2026
+1dSEC Form 4

Evidence

2
BR
Bentley Sheldon Richard10% Owner, Founder
CSAICLOUDASTRUCTURE, INC.
Open-market sale · 10b5-1 plan
SELL$22K
25.0K sh
Jan 13, 2026Jan 15, 2026
traded Jan 13, 2026
+2dSEC Form 4

Evidence

0
Yuan Eric S.Director, Chief Executive Officer
ZMZoom Communications, Inc.
Derivative conversion · 10b5-1 plan
C—
12.1K sh
Jan 13, 2026Jan 15, 2026
traded Jan 13, 2026
+2dSEC Form 4

Evidence

0
RJ
Reed Cory JPres, Life Sol Cust Sup & S.M.
DEDEERE & CO
Option exercise · 10b5-1 plan
M—
12.0K sh
Jan 14, 2026Jan 15, 2026
traded Jan 14, 2026
+1dSEC Form 4

Evidence

0
Yuan Eric S.Director, Chief Executive Officer
ZMZoom Communications, Inc.
Derivative conversion · 10b5-1 plan
C—
12.1K sh
Jan 14, 2026Jan 15, 2026
traded Jan 14, 2026
+1dSEC Form 4

Evidence

0
Yuan Eric S.Director, Chief Executive Officer
ZMZoom Communications, Inc.
Derivative conversion · 10b5-1 plan
C—
12.1K sh
Jan 14, 2026Jan 15, 2026
traded Jan 14, 2026
+1dSEC Form 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$36K
3,542 sh
Jan 13, 2026Jan 15, 2026
traded Jan 13, 2026
+2dSEC Form 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
4,167 sh
Jan 13, 2026Jan 15, 2026
traded Jan 13, 2026
+2dSEC Form 4

Evidence

0
MD
Morris DonnaExecutive Vice President
WMTWalmart Inc.
Grant or award · 10b5-1 plan
A—
15.1K sh
Jan 14, 2026Jan 15, 2026
traded Jan 14, 2026
+1dSEC Form 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
3,542 sh
Jan 13, 2026Jan 15, 2026
traded Jan 13, 2026
+2dSEC Form 4

Evidence

0
MA
Mahdessian AraDirector, Chief Executive Officer
TTANServiceTitan, Inc.
Derivative conversion · 10b5-1 plan
C—
32.0K sh
Jan 15, 2026Jan 15, 2026
traded Jan 15, 2026
+0dSEC Form 4

Evidence

0
MA
Mahdessian AraDirector, Chief Executive Officer
TTANServiceTitan, Inc.
Derivative conversion · 10b5-1 plan
C—
32.0K sh
Jan 14, 2026Jan 15, 2026
traded Jan 14, 2026
+1dSEC Form 4

Evidence

0
SS
Sijbrandij SytseDirector, 10% Owner
GTLBGitlab Inc.
Derivative conversion · 10b5-1 plan
C—
54.3K sh
Jan 14, 2026Jan 15, 2026
traded Jan 14, 2026
+1dSEC Form 4

Evidence

0
SS
Sijbrandij SytseDirector, 10% Owner
GTLBGitlab Inc.
Derivative conversion · 10b5-1 plan
C—
54.3K sh
Jan 14, 2026Jan 15, 2026
traded Jan 14, 2026
+1dSEC Form 4

Evidence

51
FP
Feinberg PeterDirector
IMRXImmuneering Corp
Open-market purchase
BUY$87K
20.0K sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

49
HD
Hildebrandt John DPresident and COO
PSMTPRICESMART INC
Open-market sale
SELL$1.02M
7,421 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

48
DA
DiGravio Karen AnnTrustee
GLQClough Global Equity Fund
Open-market purchase
BUY$3,062
378 sh
Jan 14, 2026Jan 14, 2026
traded Jan 14, 2026
+0dSEC Form 4

Evidence

46
KP
Kovaleski PaulEVP-Chief Merch. Officer
PSMTPRICESMART INC
Open-market sale
SELL$582K
4,255 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

46
IV
Infante Beatriz VDirector
PSMTPRICESMART INC
Open-market sale
SELL$273K
1,995 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

44
BR
Brumana RodrigoChief Financial Officer
JOBYJoby Aviation, Inc.
Open-market sale
SELL$7,756
523 sh
Jan 13, 2026Jan 14, 2026
traded Jan 13, 2026
+1dSEC Form 4

Evidence

43
DP
Duffy Sean P.Director, Chief Executive Officer
OMDAOmada Health, Inc.
Open-market sale
SELL$1.45M
90.5K sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

43
DP
Duffy Sean P.Director, Chief Executive Officer
OMDAOmada Health, Inc.
Open-market sale
SELL$2.15M
140.0K sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

43
BL
Baller LanceDirector, 10% Owner
GBCSSELECTIS HEALTH, INC.
Open-market purchase
BUY$14K
6,192 sh
Dec 18, 2025Jan 14, 2026
traded Dec 18, 2025
+27dSEC Form 4

Evidence

40
BC
Billingsley ChesterDirector, Chief Executive Officer, 10% Owner
MNTRMentor Capital, Inc.
Open-market purchase
BUY$204K
11 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

40
MC
Myles David C.CH. DISCOV. & NON-CLIN DEV OFF
OLMAOlema Pharmaceuticals, Inc.
Open-market sale
SELL$1.37M
49.8K sh
Jan 13, 2026Jan 14, 2026
traded Jan 13, 2026
+1dSEC Form 4

Evidence

39
GP
Garg PushkalEVP Chief R&D
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$80K
220 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

39
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$81K
226 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

39
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$148K
405 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

39
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$133K
365 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

39
BJ
Bricker JudeDirector, Chief Executive Officer
SNCYSun Country Airlines Holdings, Inc.
Open-market sale
SELL$89K
5,062 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

39
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$102K
284 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

39
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$80K
220 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

39
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$73K
199 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

39
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$65K
181 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

39
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$56K
155 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence